Iguana Healthcare Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Iguana Healthcare Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-100,000	Closed	-$1.26M	–	89
2017 Q1	$1.26M	Buy	+100,000	New	+$1.21M	0.63%	50
2016 Q4	–	Sell	-200,000	Closed	-$4.74M	–	92
2016 Q3	$4.74M	Buy	+200,000	New	+$5.38M	0.85%	44
2016 Q2	–	Sell	-50,000	Closed	-$1.6M	–	109
2016 Q1	$1.6M	Hold	50,000	–	–	0.59%	45
2015 Q4	$2.14M	Sell	50,000 -25,000	-33%	-$999K	0.7%	45
2015 Q3	$2.64M	Sell	75,000 -50,000	-40%	-$2.25M	1.04%	32
2015 Q2	$5.74M	Buy	125,000 +50,000	+67%	+$2.37M	1.81%	20
2015 Q1	$3.52M	Sell	75,000 -25,000	-25%	-$995K	1.48%	24
2014 Q4	$3.17M	Buy	100,000 +50,000	+100%	+$1.46M	1.53%	26
2014 Q3	$1.19M	Sell	50,000 -25,000	-33%	-$640K	0.63%	48
2014 Q2	$2.25M	Sell	75,000 -70,000	-48%	-$1.89M	1.05%	36
2014 Q1	$3.83M	Buy	145,000 +95,000	+190%	+$2.37M	1.77%	16
2013 Q4	$1.26M	Buy	+50,000	New	+$1.12M	0.72%	45

Other funds holding IPXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Iguana Healthcare Management's IPXL Position: Q2 2017 in Review

Iguana Healthcare Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 100,000 shares — an estimated $1.26M sold.

Iguana Healthcare Management first reported a position in IPXL in Q4 2013 and held it in 12 quarters. The position peaked at $5.74M in Q2 2015. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

Iguana Healthcare Management reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
Iguana Healthcare Management sold 100,000 Impax Laboratories, Inc. shares in Q2 2017, an estimated $1.26M.
Iguana Healthcare Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 12 quarters.
Iguana Healthcare Management's Impax Laboratories, Inc. position peaked at $5.74M in Q2 2015.
172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on Iguana Healthcare Management's 13F filing for Q2 2017, filed 14 Aug 2017.